Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lodoxamide in vernal keratoconjunctivitis

S Lee1, T R Allard

  • 1Kaiser Hospital, Woodland Hills, CA, USA.

The Annals of Pharmacotherapy
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conformation of tachyplesin I from Tachypleus tridentatus when interacting with lipid matrices.

Biochemistry·1992
Same author

The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Journal of virology·1992
Same author

The clinical validity of tardive anorexia nervosa.

The Australian and New Zealand journal of psychiatry·1992
Same author

The neglect of anger in Western psychiatry.

The British journal of psychiatry : the journal of mental science·1992
Same author

Tissue-specific expression in mammalian brain, heart, and muscle of S1, a member of the elongation factor-1 alpha gene family.

The Journal of biological chemistry·1992
Same author

Deletion of the pro-alpha 1(I) N-propeptide affects secretion of type I collagen in Chinese hamster lung cells but not in Mov-13 mouse cells.

The Journal of biological chemistry·1992
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Lodoxamide may be more effective than cromolyn sodium for vernal keratoconjunctivitis (VKC). Further high-quality research is needed to confirm lodoxamide

Area of Science:

  • Ophthalmology
  • Allergy and Immunology

Background:

  • Vernal keratoconjunctivitis (VKC) is a chronic allergic eye condition.
  • Mast cell stabilizers like cromolyn sodium are commonly used for VKC treatment.
  • Lodoxamide is another mast cell stabilizer with potential therapeutic benefits.

Purpose of the Study:

  • To evaluate the comparative efficacy of lodoxamide versus cromolyn sodium in treating VKC.
  • To identify the optimal treatment strategy for VKC based on available evidence.

Main Methods:

  • Review of three clinical studies comparing lodoxamide and cromolyn sodium for VKC.
  • Analysis of treatment outcomes and adverse effects reported in the reviewed studies.

Main Results:

  • Preliminary findings suggest lodoxamide may offer superior efficacy compared to cromolyn sodium for VKC.

Related Experiment Videos

  • Current evidence is insufficient to definitively establish lodoxamide's superiority due to limitations in the reviewed studies.

    • Conclusions:

    • Further rigorous clinical trials are warranted to confirm the potential benefits of lodoxamide over cromolyn sodium.
    • A large-scale, triple-blind, randomized, placebo-controlled, multicenter trial is proposed to definitively assess treatment superiority.